

Zohreh Azarkar (MD)^{*1}
Majid Jafarnejad(MD)²
Gholamreza
Sharifzadeh(MSc)³

1- Department of Infectious Disease, Birjand University of Medical Sciences, Birjand, Iran
2- Department of Cardiology, Birjand University of Medical Sciences, Birjand, Iran
3- Department of Social Medicine, Birjand University of Medical Sciences, Birjand, Iran.

* **Correspondence:**
Zohreh Azarkar, Assistant Professor of Infectious Diseases, Birjand University of Medical Sciences, Birjand, Iran.

E-mail: drz.azarkar@yahoo.com
Tel: 0098 561 44445402
Fax: 0098 561 44445402

Received: 16 Feb 2011
Revised: 18 April 2011
Accepted: 29 May 2011

The relationship between helicobacter pylori infection and myocardial infarction

Abstract

Background: Coronary Artery Disease is known as the main cause of death in industrialized countries. Relation between this disease and some infections such as *Helicobacter pylori* (*H.pylori*) has been shown in several studies. The purpose of this study was to determine the relationship between *H.pylori* and myocardial infarctions.

Methods: Seventy-three myocardial infarction patients and 78 individuals with no history of this disease were compared. Patients and control matched for age and sex person to person by the match method. Levels of serum IgA and IgG antibodies against *H. pylori* were measured by Elisa method. Also, cholesterol, triglyceride, LDL, HDL measured in both groups and data were compared between two groups in terms of relation with cardiac risk factors.

Results: From 151 participants, 73 were patients and 78 were control subjects. The percentage of IgG positive cases against *H. pylori* was 57.5% in the case group and 32.1% in the control group ($p=0.002$, OR: 2.87 CI: 95%; 1.5-5.6). Meanwhile, there was no significant difference in IgA positive cases between the two groups (42.5% and 48.7% in the case and control groups, respectively) ($p=0.44$; OR: 0.78 95% CI; 0.41-1.48). The study showed 74.2% of cases in the case group and 45.2% in the control group were positive for both IgG and IgA ($p=0.01$; OR: 3.5 95% CI; 1.3-9.5). No significant differences were found between two groups in terms of relation between *H. pylori* related antibodies level and heart disease classic risk factors (smoking, hypertension, ...), sex, and age, but between dyslipidemia and *H. pylori* related antibodies was significant differences in case group ($p=0.05$).

Conclusion: According to the results, it seems there is a relation between *H. pylori* infection and myocardial infarction. Also, between dyslipidemia and *H. Pylori* antibodies in case group were significant difference. Therefore, *H. pylori* can be a new risk factor for atherosclerosis or can be exacerbate effect of other risk factors. Proper diagnosis and treatment of these infections can be useful in prone patients. More studies with larger sample groups are needed to review the possible role of this pathogen as a heart disease risk factor.

Key words: *Helicobacter pylori*, IgG, IgA, Myocardial infarction.

Caspian J Intern Med 2011; 2 (2):222-225.

Coronary heart disease is the most common cause of death in developed and developing countries. As an etiologic agent, atherosclerosis is considered the most prevalent cause of coronary heart disease and a major cause of ischemic heart diseases (1). Many epidemiologic and clinical studies have suggested the role of severe and sustained inflammations in developing atherosclerotic lesions. Inflammation –as a response to irritation, infection, or lipid peroxidation- is considered a cardiovascular risk factor (2). It has been suggested that a persistent low grade inflammatory response resulting from chronic gastritis caused by *H. pylori* may increase the concentration of certain coagulation factors, such as fibrinogen, which are predictors of ischemic heart disease (3).

Concomitant condition, like a genetic predisposition in increasing fibrinogen levels, seem to further increase the effect of H. pylori on myocardial infarction risk (4, 5). Helicobacter pylori causes one of the most common chronic bacterial infections. Serological evidences indicate that half of the adult population is infected (6).

This bacteria with organisms such as Chlamydia pneumoniae and viruses such as HSV1 and CMV in the pathogenesis sclerosis have been introduced with specific and nonspecific mechanisms such as increased clotting ability, increased production of adhesion molecules and CRP causes of this phenomenon represented (7). Mendall et al. suggested the relationship between Helicobacter pylori infection and coronary heart disease, for the first time (8). Later, many studies reported conflicting findings about the microorganisms involved in coronary heart disease (9-11).

However, if H.pylori is involved in causing atherosclerosis, treatment of gastrointestinal symptoms in atherosclerosis patients with H. pylori infection could have a preventive effect for myocardial infarction.

Due to high prevalence of arthrosclerosis and importance of considering heart disease risk factors, the current study set out to investigate the possible effect of H. pylori infection on developing acute MI.

Methods

In this case-control study, 78 individuals with no history of heart disease and 73 acute myocardial infarction patients (all between 30 and 80 years old) were compared in two separate groups. There was no significant difference in the sex ratio and mean age of participants in two groups (53 males and 20 females in the case group and 49 males and 29 females in the control group with the mean age of 59.8±11.5 and 56.4±13.9 years, respectively).

The case group admitted in CCU ward was selected by convenient non probability sampling method.

Patients had the history of admission to CCU with confirmed clinical symptoms of MI, positive ECG, and increased levels of cardiac enzymes. For each case among the control patients in surgery ward were selected, who were admitted for minor surgeries and had no history or positive physical examination or ECG results for cardiovascular diseases. Patients and control matched were in age and sex by the match method. History included factors such as heart disease, diabetes, hypertension, smoking, and hyperlipidemia.

Gastrointestinal drugs consumers excluded in both groups. Blood samples (5 cc) were obtained and sent to laboratory at -20 ° C for H. pylori IgG and IgA was measured by ELISA method using Monobind kit. Also, we measured cholesterol, triglyceride, LDL, HDL in both groups.

Data were analyzed using Chi-square (X²), T- test and Odds Ratio estimation in SPSS -15 software.

Results

There were 53 males (72.6%) and 20 females (27.4%) in the case group while the control group was made up of 49 (62.8%) men and 29 (37.2 %) women (p=0.1)

The mean ages in the case group and the control group were 59.8±11.5 and 56.4±13.9 years, respectively (p=0.1).

Also, no significant differences were found between two groups in diabetes, hypertension, smoking, and dislipidemia.

57.5% (42 patient) of those in the case group and 32.1% (25 people) in the control group were IgG positive against H. pylori. The difference was statistically significant (p=0.002) difference was statistically significant (p=0.002). Meanwhile, there was no significant difference between IgA levels of two groups (p=0.44) (Table1).

Table1: Comparison of relative frequency of positive IgG and IgA in both groups

	Negative N(%)	Positive N(%)	Total N(%)	OR (CI)	p
IgG					
Case	31 (42.5)	42 (57.5)	73 (100)	2.87	
Control	53 (67.9)	25 (32.1)	78 (100)	(95%; 1.5-5.6)	0.002
IgA					
Case	42 (57.5)	31 (42.5)	73 (100)	0.78	
Control	40 (51.3)	38 (48.7)	78 (100)	(95%; 0.41-1.48)	0.44

31 (42.5%) cases and 38 (48.7%) controls had positive IgA results against H. pylori. 23 (74.2%) cases and 19 (45.2%) controls were positive for both IgG and IgA with a statistically significant difference (p=0.01) (Table 2).

Table 2: Relative frequency of positive IgG and IgA in case group

	IgG	Negative	Positive	Total
IgA		N(%)	N (%)	N(%)
Positive		8 (25.8)	23 (74.2)	31 (100)
Negative		23 (54.8)	19 (45.2)	42 (100)
Total		31 (42.5)	42 (57.5)	73 (100)

$\chi^2 = 6.120$ df= 1 p= 0.01 OR: 3.5 CI: 95%; 1.3-9.5

Except for dislipidemia in the case group, there was no meaningful relationship between H. pylori antibody levels and heart disease classic risk factors (p=0.05) (Table4).

Table 3: Comparison of relative frequency of IgA and dislipidemi in case group

	IgA	Negative	Positive	Total
Dislipidemi		IgA	IgA	N(%)
		N(%)	N(%)	
Positive		31 (73.8)	16 (51.6)	47 (64.4)
Negative		11 (26.2)	15 (48.4)	26 (35.6)
Total		42 (100)	31 (100)	73 (100)

$\chi^2 = 3.832$ df= 1 p= 0.05 OR: 0.38 CI: 95%; 0.14-1.01

No significant difference was seen between age, sex, smoking, hypertension, and H. pylori antibodies in any of the two groups.

Discussion

In this study, a significant difference in H. pylori IgG levels was shown between cases and controls (p=0.002) but the difference was not significant for IgA (p=0.44).

The case group had a statistically significant difference with the control group in terms of concurrent high levels of IgA and IgG (p=0.013). In different seroepidemiological studies, results have been conflicting (9-11). Some researchers have suggested a significant relationship between Helicobacter pylori and coronary heart disease (12-15). To justify the different results, some believe that the H. pylori CagA gene is effective in generating (16).

In some studies, H. pylori infection was mainly found in those of a lower socioeconomic status. Therefore, the connection between coronary disease and H. pylori infection could be due to close relationship of these two diseases on

the social level (17). Cardiovascular risk factors compared with antibodies against H. pylori were statistically significant differences observed. Although hypertension, diabetes, smoking, and hyperlipidemia are concerned as major risk factors, about 20% of all cardiovascular events occur in the absence of such factors (18). H. pylori antibody levels could have a relationship with serum HDL levels. En-zhi-jin reported significant lower HDL levels in the H. pylori seropositive cases (19) the findings which were not observed in the current study. Chronic viral and bacterial infections, in addition to the ground as atherosclerosis, may also play a role in aggravation (20).

Chronic infections increase the production of various metabolites, such as inflammatory cytokines, that affect the blood flow in vessels and cause endothelial dysfunction and further shrinkage of small vessels (21-23). Elevated concentrations of cytokines in the gastric mucosa of H. pylori infected patients could increase serum fibrinogen and leukocytes. It seems that inflammatory response and related reactions in patients with H. pylori infection could justify accompaniment of this infection and acute coronary syndrome (24).

Because of the role of chronic inflammation in developing atherosclerosis, H. pylori infection can be considered a new risk factors. Also, these was a significant difference between dislipidemia and Helicobacter pylori antibodies in case group. Considering the above results, people with impaired fat are more likely to have conflict with Helicobacter. Therefore, proper diagnosis and treatment of these infections can be useful in patients prone to this most studies in this area with a larger volume are suggested.

Acknowledgements

We are thankful to Vali Asr Hospital CCU personnel who kindly participated in this study.

Conflict of interest: None declared.

References

1. Cannon CP. The next step in cardiovascular protection. *Atheroscler Suppl* 2003; 4:3-9.
2. De Luis DA, Lahera M, Canton R, et al. Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. *Diabetes Care* 1998; 21: 1129-32.

3. Parente F, Bianchi Porro G. The association between Helicobacter Pylori infection and ischemic heart disease: facts or fancy? *Helicobacter* 1997; 2: 67-72.
4. Vischetti M, Zito F, Donati MB, Iacoviello L. Analysis of gene-environment interaction in coronary heart disease: fibrinogen polymorphisms as an example. *Ital Heart J* 2002; 3:18-23.
5. Zito F, Di Castelnuovo A, D'Orazio A, et al. Helicobacter Pylori infection and the risk of myocardial infarction: role of fibrinogen and its genetic control. *Thromb Haemost* 1999; 82: 8-14.
6. Brown LM. Helicobacter Pylori: epidemiology and routes of transmission. *Epidemiol Rev* 2000; 22: 283-97.
7. Nabipour I, Vahdat K, Jafari SM, Ahmad Zadeh T, et al. The association of metabolic syndrome and Chlamydia pneumonia, helicobacter pylori, cytomegalovirus and herpes simplex virus type 1: A population-based study. *Iran South Med J* 2005; 1: 60-7.
8. Mendall MA, Coggin PM, Molineux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. *Br Heart J* 1994; 71: 437-9. [In persian].
9. Faghihi Kashani AH, Bahar MA, Kabir A. Fibrinogen role in probable association between helicobacter pylori infection and ischemic heart disease. *J Iran Univ Med Sci* 2005; 47: 107-14. [In Persian]
10. Bazzazi H, Ramezani MA, Bazoori M, et al. Seroepidemiology of Helicobacter Pylori infection in Patients With Coronary Syndrome in Gorgan. *J Gorgan Univ Med Sci* 2007; 1: 33-7. [In persian]
11. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. *BMJ* 1998; 316: 1130-2.
12. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation and the risk of coronary heart disease. *Circulation* 2000; 101: 252-7.
13. Bahar MA, Faghihi Kashani AH, Haghghat P, Kabir A, Poor Eslami M. Association between helicobacter pylori infection and coronary heart disease. *J Iran Univ Med Sci* 2004; 39: 13-22. [In persian]
14. Rahimi B, Danesh Pajouh M, Ahsani S, Tahernia R. Cardiovascular disease and Chlamydia, helicobacter pylori and cytomegalovirus infection. *Pejouhandeh* 2001; 24: 331-4. [In persian]
15. Eslami G, Fallah F, Kazemi B, et al. Detection of Cytomegalovirus and Helicobacter Pylori in atherosclerotic plaques in patients with coronary artery disease. *Paramedical Sciences, Journal of the Faculty of Paramedical Sciences* 2003; 2: 97-102. [In persian]
16. Aceti A, Are R, Sabino G, et al. Helicobacter pylori active infection in patients with acute coronary heart disease. *J infect* 2004; 49:8-12.
17. Saraf-Zadegan N, Amiri M, Maghsoudloo S. Helicobacter pylori relation to acute myocardial infarction in an Iranian sample. *Coronary Health Care* 2001; 5:202-7.
18. Kumar V, Abbas AK, Fausto N, Mitchell R. *Robbins Basic Pathology*. 8th ed. USA: W.B.Saunders company 2007; pp: 70-77.
19. Jia EZ, Zhao FJ, Hao B, et al. Helicobacter pylori infection is associated with decreased serum levels of high density lipoprotein, but not with the severity of coronary atherosclerosis. *Lipids health dis* 2009; 8: 59.
20. Nocent R, Gentiloni N, Cremonini F, et al. Resolution of syndrome X after eradication of virulent cag A-positive helicobacter pylori. *South Med J* 2000; 93:1022-3.
21. Su YC, Wang WM, Wang SY, et al. The association between helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. *Am J Gastroenterol* 2000; 95:1960-5.
22. Annuziata P, Figura N, Galli R, Murganini F, Lenzi C. Association of anti-GM1 antibodies but not of anti-cytomegalovirus, campylobacter jejuni and helicobacter pylori IgG, with a poor outcome in Guillain-Barre syndrome. *J Neurol Sci* 2003; 213: 55-60.
23. Tsai WC, Li YH, Sheu BS, et al. Association of elevation of anti-helicobacter pylori antibody with myocardial ischemic events in coronary artery disease. *AM J Cardiol* 2001; 87: 1005-7.
24. Seyyed Mohammad Zade MH, Eishi A, Behroozian R, Rahimi E. Relationship between Helicobacter pylori infection and cardiac syndrome X. *Shahrekourd Univ Med J* 2009; 11: 58-63. [In persian]